Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate.

Phillips AC, Boghaert ER, Vaidya KS, Falls HD, Mitten MJ, DeVries PJ, Benatuil L, Hsieh CM, Meulbroek JA, Panchal SC, Buchanan FG, Durbin KR, Voorbach MJ, Reuter DR, Mudd SR, Loberg LI, Ralston SL, Cao D, Gan HK, Scott AM, Reilly EB.

Mol Cancer Ther. 2018 Apr;17(4):795-805. doi: 10.1158/1535-7163.MCT-17-0710. Epub 2018 Feb 26.

2.

ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.

Phillips AC, Boghaert ER, Vaidya KS, Mitten MJ, Norvell S, Falls HD, DeVries PJ, Cheng D, Meulbroek JA, Buchanan FG, McKay LM, Goodwin NC, Reilly EB.

Mol Cancer Ther. 2016 Apr;15(4):661-9. doi: 10.1158/1535-7163.MCT-15-0901. Epub 2016 Feb 4.

3.

Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody.

Reilly EB, Phillips AC, Buchanan FG, Kingsbury G, Zhang Y, Meulbroek JA, Cole TB, DeVries PJ, Falls HD, Beam C, Gu J, Digiammarino EL, Palma JP, Donawho CK, Goodwin NC, Scott AM.

Mol Cancer Ther. 2015 May;14(5):1141-51. doi: 10.1158/1535-7163.MCT-14-0820. Epub 2015 Mar 2.

4.

Reversal of oncogene transformation and suppression of tumor growth by the novel IGF1R kinase inhibitor A-928605.

Pappano WN, Jung PM, Meulbroek JA, Wang YC, Hubbard RD, Zhang Q, Grudzien MM, Soni NB, Johnson EF, Sheppard GS, Donawho C, Buchanan FG, Davidsen SK, Bell RL, Wang J.

BMC Cancer. 2009 Sep 4;9:314. doi: 10.1186/1471-2407-9-314.

5.

Correlation of tumor growth suppression and methionine aminopetidase-2 activity blockade using an orally active inhibitor.

Wang J, Tucker LA, Stavropoulos J, Zhang Q, Wang YC, Bukofzer G, Niquette A, Meulbroek JA, Barnes DM, Shen J, Bouska J, Donawho C, Sheppard GS, Bell RL.

Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):1838-43. doi: 10.1073/pnas.0708766105. Epub 2008 Feb 5.

6.

ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models.

Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, Bontcheva-Diaz VD, Cox BF, DeWeese TL, Dillehay LE, Ferguson DC, Ghoreishi-Haack NS, Grimm DR, Guan R, Han EK, Holley-Shanks RR, Hristov B, Idler KB, Jarvis K, Johnson EF, Kleinberg LR, Klinghofer V, Lasko LM, Liu X, Marsh KC, McGonigal TP, Meulbroek JA, Olson AM, Palma JP, Rodriguez LE, Shi Y, Stavropoulos JA, Tsurutani AC, Zhu GD, Rosenberg SH, Giranda VL, Frost DJ.

Clin Cancer Res. 2007 May 1;13(9):2728-37.

7.

Polyphosphoinositides suppress the adhesion of Haemophilus influenzae to pharyngeal cells.

Liu JW, Anderson SN, Meulbroek JA, Hwang SM, Mukerji P, Huang YS.

Lipids Health Dis. 2004 Sep 3;3:20.

8.

In vivo characterization of A-192411: a novel fungicidal lipopeptide (II).

Meulbroek JA, Nilius AM, Li Q, Wang W, Hasvold L, Steiner B, Dickman DA, Ding H, Frost D, Goldman RC, Lartey P, Plattner JJ, Bennani YL.

Bioorg Med Chem Lett. 2003 Feb 10;13(3):495-7.

PMID:
12565958
9.

Total synthesis and antifungal evaluation of cyclic aminohexapeptides.

Klein LL, Li L, Chen HJ, Curty CB, DeGoey DA, Grampovnik DJ, Leone CL, Thomas SA, Yeung CM, Funk KW, Kishore V, Lundell EO, Wodka D, Meulbroek JA, Alder JD, Nilius AM, Lartey PA, Plattner JJ.

Bioorg Med Chem. 2000 Jul;8(7):1677-96.

PMID:
10976515
10.

Synthesis and antimicrobial activity of 4H-4-oxoquinolizine derivatives: consequences of structural modification at the C-8 position.

Ma Z, Chu DT, Cooper CS, Li Q, Fung AK, Wang S, Shen LL, Flamm RK, Nilius AM, Alder JD, Meulbroek JA, Or YS.

J Med Chem. 1999 Oct 7;42(20):4202-13.

PMID:
10514290
11.

Phenotype in Candida albicans of a disruption of the BGL2 gene encoding a 1,3-beta-glucosyltransferase.

Sarthy AV, McGonigal T, Coen M, Frost DJ, Meulbroek JA, Goldman RC.

Microbiology. 1997 Feb;143 ( Pt 2):367-76.

PMID:
9043114
12.
13.

Treatment of experimental Toxoplasma gondii infection by clarithromycin-based combination therapy with minocycline or pyrimethamine.

Alder J, Hutch T, Meulbroek JA, Clement JC.

J Acquir Immune Defic Syndr. 1994 Nov;7(11):1141-8.

PMID:
7932081
14.

An immunosuppressed rat model of respiratory cryptosporidiosis.

Meulbroek JA, Novilla MN, Current WL.

J Protozool. 1991 Nov-Dec;38(6):113S-115S.

PMID:
1818128
16.

Biodegradable microspheres as a vaccine delivery system.

Eldridge JH, Staas JK, Meulbroek JA, McGhee JR, Tice TR, Gilley RM.

Mol Immunol. 1991 Mar;28(3):287-94.

PMID:
2017198
17.

Biodegradable microspheres: vaccine delivery system for oral immunization.

Eldridge JH, Gilley RM, Staas JK, Moldoveanu Z, Meulbroek JA, Tice TR.

Curr Top Microbiol Immunol. 1989;146:59-66.

PMID:
2731430
19.

Induction of secretory immunity to type 3 Streptococcus pneumoniae by oral immunization.

Meulbroek JA, Eldridge JH, Alley CD, Michalek SM, McGhee JR.

Adv Exp Med Biol. 1987;216B:1765-70. No abstract available.

PMID:
3425460
20.

Simultaneous expression of multiple immune complex receptors on murine thymocytes and spleen cells.

Walia AS, Meulbroek JA, Andersson B, Lamon EW.

Clin Immunol Immunopathol. 1986 Dec;41(3):368-78.

PMID:
3780051

Supplemental Content

Loading ...
Support Center